CN114980862A - Cgrp抑制剂的鼻内药物组合物 - Google Patents

Cgrp抑制剂的鼻内药物组合物 Download PDF

Info

Publication number
CN114980862A
CN114980862A CN202080086534.4A CN202080086534A CN114980862A CN 114980862 A CN114980862 A CN 114980862A CN 202080086534 A CN202080086534 A CN 202080086534A CN 114980862 A CN114980862 A CN 114980862A
Authority
CN
China
Prior art keywords
cgrp
pain
inhibitor
disease
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080086534.4A
Other languages
English (en)
Chinese (zh)
Inventor
V·克瑞克
C·M·康威
R·克鲁普
R·库马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CN114980862A publication Critical patent/CN114980862A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080086534.4A 2019-12-17 2020-12-17 Cgrp抑制剂的鼻内药物组合物 Pending CN114980862A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949351P 2019-12-17 2019-12-17
US62/949,351 2019-12-17
PCT/US2020/065452 WO2021127070A1 (en) 2019-12-17 2020-12-17 Intranasal pharmaceutical compositions of cgrp inhibitors

Publications (1)

Publication Number Publication Date
CN114980862A true CN114980862A (zh) 2022-08-30

Family

ID=76478147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080086534.4A Pending CN114980862A (zh) 2019-12-17 2020-12-17 Cgrp抑制剂的鼻内药物组合物

Country Status (11)

Country Link
US (1) US20220401439A1 (https=)
EP (1) EP4076395A4 (https=)
JP (1) JP2023507094A (https=)
KR (1) KR20220114613A (https=)
CN (1) CN114980862A (https=)
AU (1) AU2020408705A1 (https=)
BR (1) BR112022011892A2 (https=)
CA (1) CA3164445A1 (https=)
IL (1) IL293647A (https=)
MX (1) MX2022007336A (https=)
WO (1) WO2021127070A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115429882A (zh) * 2022-10-19 2022-12-06 上海交通大学医学院附属第九人民医院 伤害性感觉神经细胞调控药物的用途
CN116003387A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
CN120733002A (zh) * 2025-09-03 2025-10-03 华中科技大学同济医学院附属同济医院 Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12521389B2 (en) * 2019-06-14 2026-01-13 The Regents Of The University Of California Therapeutic approach to lung disease
WO2022109077A1 (en) * 2020-11-19 2022-05-27 Biohaven Pharmaceutical Holding Company Ltd. Compositions for improved delivery of cgrp inhibitors
JP1706573S (ja) * 2021-02-15 2022-02-01 鼻スプレー器
WO2023064195A1 (en) * 2021-10-11 2023-04-20 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating trigeminal neuralgia
CA3252054A1 (en) 2022-11-09 2024-05-16 Tapi Czech Industries S.R.O. SOLID FORMS OF ZAVÉGÉPANT HYDROCHLORIDE AND THEIR PREPARATION PROCESS
JP1773931S (ja) * 2023-05-17 2024-06-25 鼻スプレー器
CA225743S (fr) * 2023-05-17 2024-09-12 Aptar France Sas Dispositif pour spray nasal
CA225744S (fr) * 2023-05-17 2024-09-12 Aptar France Sas Dispositif pour spray nasal
GB202308123D0 (en) * 2023-05-31 2023-07-12 Orexo Ab New copmosition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059017A1 (en) * 2010-03-30 2012-03-08 Bristol-Myers Squibb Company CGRP Receptor Antagonist
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
US20160199600A1 (en) * 2013-09-11 2016-07-14 Bixa Research And Health Inc. Single use intranasal atomizer
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
KR102444717B1 (ko) * 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
CN109476639B (zh) * 2016-07-22 2021-02-26 橘生药品工业股份有限公司 吡咯烷衍生物
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
AU2020259461A1 (en) * 2019-04-18 2021-11-11 Allergan Sales, Llc CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059017A1 (en) * 2010-03-30 2012-03-08 Bristol-Myers Squibb Company CGRP Receptor Antagonist
CN102834388A (zh) * 2010-03-30 2012-12-19 百时美施贵宝公司 Cgrp受体拮抗剂
US20190135927A1 (en) * 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115429882A (zh) * 2022-10-19 2022-12-06 上海交通大学医学院附属第九人民医院 伤害性感觉神经细胞调控药物的用途
CN116003387A (zh) * 2022-11-20 2023-04-25 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
CN116003387B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
CN120733002A (zh) * 2025-09-03 2025-10-03 华中科技大学同济医学院附属同济医院 Cgrp受体小分子拮抗剂在制备治疗嗜酸性慢性鼻窦炎伴鼻息肉的药品中的应用

Also Published As

Publication number Publication date
WO2021127070A1 (en) 2021-06-24
US20220401439A1 (en) 2022-12-22
KR20220114613A (ko) 2022-08-17
EP4076395A1 (en) 2022-10-26
CA3164445A1 (en) 2021-06-24
EP4076395A4 (en) 2024-02-07
JP2023507094A (ja) 2023-02-21
BR112022011892A2 (pt) 2022-09-06
IL293647A (en) 2022-08-01
MX2022007336A (es) 2022-09-19
AU2020408705A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
CN114980862A (zh) Cgrp抑制剂的鼻内药物组合物
CN104662007B (zh) 胱硫醚‑γ‑裂合酶(CSE)抑制剂
US10428072B2 (en) Inhibiting the transient receptor potential A1 ion channel
US20080118558A1 (en) N-Arylshydroxyalkylidene carboxamide compositions and methods
CA2724726C (en) 5-lipoxygenase-activating protein inhibitor
US12246005B2 (en) 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
JP2025505745A (ja) フェネチルアミン誘導体、組成物、及び使用方法
AU2017379247A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
US20250236589A1 (en) Therapeutic phenethylamine compositions and methods of use
US20240408080A1 (en) Pharmaceutical compositions of cgrp inhibitors and methods of their use
US20150238456A1 (en) Methods and compositions for administration of oxybutynin
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
BR112012013325B1 (pt) Composição farmacêutica e uso
HK40075170A (en) Intranasal pharmaceutical compositions of cgrp inhibitors
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
CN103732611B (zh) β-肾上腺素能反向激动剂用于戒烟的用途
US20250193970A1 (en) 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS
CN102202665A (zh) 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
JP2022501419A (ja) 鎮痛組成物
JPWO2011074695A1 (ja) シバリング抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075170

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240409

Address after: Ai Erlankekejun

Applicant after: PFIZER IRELAND PHARMACEUTICALS

Country or region after: Ireland

Address before: Connecticut, USA

Applicant before: BIOHAVEN PHARMACEUTICAL HOLDING CO.,LTD.

Country or region before: U.S.A.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220830